A radioprotective effect of imatinib (Gleevec®) in human squamous carcinoma cells

Detlef Bartkowiak, Peter R. Hipp, Marc Mendonca, Erwin M. Röttinger

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Purpose: To study the radiation response-modifying effect of imatinib (Gleevec®) in a squamous cell carcinoma line, PECA. Material and Methods: Cytotoxicity was determined by colony forming and multiplying capacity. Drug stability was shown by HPLC. Multidrug resistance phenotype was studied by rhodamine-123 efflux. Cell-cycle responses were measured by flow cytometry. Homologous recombination repair was determined by Rad51 immunohistochemistry. Results: Inactivating 50% of the PECA cells required approximately 7 μM imatinib. The drug did not decay nor was it degraded during test periods. Drug efflux occurred only to a minor extent. Multiplying capacity but not survival fractions revealed a radioprotective effect of imatinib. There were only minor cell-cycle alterations in the presence of imatinib but the rate of Rad51-positive repair foci was significantly increased. Conclusion: PECA cells apparently lack a highly specific target for imatinib. In cells surviving at high drug concentrations, imatinib may exert a radioprotective effect on multiplying capacity by inducing DNA repair. Under prolonged exposure, drug-resistant cells may show an accelerated recovery from acute or delayed radiation damage.

Original languageEnglish
Pages (from-to)432-439
Number of pages8
JournalStrahlentherapie und Onkologie
Volume183
Issue number8
DOIs
StatePublished - Aug 2007

Fingerprint

Squamous Cell Carcinoma
Pharmaceutical Preparations
Cell Cycle
Radiation
Drug Stability
Rhodamine 123
Recombinational DNA Repair
Multiple Drug Resistance
Imatinib Mesylate
DNA Repair
Flow Cytometry
Immunohistochemistry
High Pressure Liquid Chromatography
Phenotype
Cell Line
Survival

Keywords

  • Gleevec®
  • Imatinib
  • Protection
  • Radiation

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging
  • Cancer Research
  • Radiological and Ultrasound Technology

Cite this

A radioprotective effect of imatinib (Gleevec®) in human squamous carcinoma cells. / Bartkowiak, Detlef; Hipp, Peter R.; Mendonca, Marc; Röttinger, Erwin M.

In: Strahlentherapie und Onkologie, Vol. 183, No. 8, 08.2007, p. 432-439.

Research output: Contribution to journalArticle

Bartkowiak, Detlef ; Hipp, Peter R. ; Mendonca, Marc ; Röttinger, Erwin M. / A radioprotective effect of imatinib (Gleevec®) in human squamous carcinoma cells. In: Strahlentherapie und Onkologie. 2007 ; Vol. 183, No. 8. pp. 432-439.
@article{9450bc1a35b24c99bc776e8a5022ed88,
title = "A radioprotective effect of imatinib (Gleevec{\circledR}) in human squamous carcinoma cells",
abstract = "Purpose: To study the radiation response-modifying effect of imatinib (Gleevec{\circledR}) in a squamous cell carcinoma line, PECA. Material and Methods: Cytotoxicity was determined by colony forming and multiplying capacity. Drug stability was shown by HPLC. Multidrug resistance phenotype was studied by rhodamine-123 efflux. Cell-cycle responses were measured by flow cytometry. Homologous recombination repair was determined by Rad51 immunohistochemistry. Results: Inactivating 50{\%} of the PECA cells required approximately 7 μM imatinib. The drug did not decay nor was it degraded during test periods. Drug efflux occurred only to a minor extent. Multiplying capacity but not survival fractions revealed a radioprotective effect of imatinib. There were only minor cell-cycle alterations in the presence of imatinib but the rate of Rad51-positive repair foci was significantly increased. Conclusion: PECA cells apparently lack a highly specific target for imatinib. In cells surviving at high drug concentrations, imatinib may exert a radioprotective effect on multiplying capacity by inducing DNA repair. Under prolonged exposure, drug-resistant cells may show an accelerated recovery from acute or delayed radiation damage.",
keywords = "Gleevec{\circledR}, Imatinib, Protection, Radiation",
author = "Detlef Bartkowiak and Hipp, {Peter R.} and Marc Mendonca and R{\"o}ttinger, {Erwin M.}",
year = "2007",
month = "8",
doi = "10.1007/s00066-007-1680-7",
language = "English",
volume = "183",
pages = "432--439",
journal = "Strahlentherapie und Onkologie",
issn = "0179-7158",
publisher = "Urban und Vogel",
number = "8",

}

TY - JOUR

T1 - A radioprotective effect of imatinib (Gleevec®) in human squamous carcinoma cells

AU - Bartkowiak, Detlef

AU - Hipp, Peter R.

AU - Mendonca, Marc

AU - Röttinger, Erwin M.

PY - 2007/8

Y1 - 2007/8

N2 - Purpose: To study the radiation response-modifying effect of imatinib (Gleevec®) in a squamous cell carcinoma line, PECA. Material and Methods: Cytotoxicity was determined by colony forming and multiplying capacity. Drug stability was shown by HPLC. Multidrug resistance phenotype was studied by rhodamine-123 efflux. Cell-cycle responses were measured by flow cytometry. Homologous recombination repair was determined by Rad51 immunohistochemistry. Results: Inactivating 50% of the PECA cells required approximately 7 μM imatinib. The drug did not decay nor was it degraded during test periods. Drug efflux occurred only to a minor extent. Multiplying capacity but not survival fractions revealed a radioprotective effect of imatinib. There were only minor cell-cycle alterations in the presence of imatinib but the rate of Rad51-positive repair foci was significantly increased. Conclusion: PECA cells apparently lack a highly specific target for imatinib. In cells surviving at high drug concentrations, imatinib may exert a radioprotective effect on multiplying capacity by inducing DNA repair. Under prolonged exposure, drug-resistant cells may show an accelerated recovery from acute or delayed radiation damage.

AB - Purpose: To study the radiation response-modifying effect of imatinib (Gleevec®) in a squamous cell carcinoma line, PECA. Material and Methods: Cytotoxicity was determined by colony forming and multiplying capacity. Drug stability was shown by HPLC. Multidrug resistance phenotype was studied by rhodamine-123 efflux. Cell-cycle responses were measured by flow cytometry. Homologous recombination repair was determined by Rad51 immunohistochemistry. Results: Inactivating 50% of the PECA cells required approximately 7 μM imatinib. The drug did not decay nor was it degraded during test periods. Drug efflux occurred only to a minor extent. Multiplying capacity but not survival fractions revealed a radioprotective effect of imatinib. There were only minor cell-cycle alterations in the presence of imatinib but the rate of Rad51-positive repair foci was significantly increased. Conclusion: PECA cells apparently lack a highly specific target for imatinib. In cells surviving at high drug concentrations, imatinib may exert a radioprotective effect on multiplying capacity by inducing DNA repair. Under prolonged exposure, drug-resistant cells may show an accelerated recovery from acute or delayed radiation damage.

KW - Gleevec®

KW - Imatinib

KW - Protection

KW - Radiation

UR - http://www.scopus.com/inward/record.url?scp=34547761276&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34547761276&partnerID=8YFLogxK

U2 - 10.1007/s00066-007-1680-7

DO - 10.1007/s00066-007-1680-7

M3 - Article

C2 - 17680223

AN - SCOPUS:34547761276

VL - 183

SP - 432

EP - 439

JO - Strahlentherapie und Onkologie

JF - Strahlentherapie und Onkologie

SN - 0179-7158

IS - 8

ER -